1
|
Morgan T, Whitacre E, Burak W, Manahan E, Goedde T, Greenspan A, Woods J, Nolte D, Turek J, Loesch DM, An R. Biodynamic response prediction in breast cancer patients receiving neoadjuvant chemotherapy. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.e12643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e12643 Background: Biodynamic signatures (temporal patterns of microscopic motion within a three-dimensional tumor explant) offer a phenomic biomarker that is highly predictive for therapeutic response. The purpose of this study is to evaluate predictive accuracy of a biodynamic drug response classifier in breast cancer patients receiving neoadjuvant chemotherapy (NAC). Methods: Consecutive breast cancer patients from 4 institutions were screened for enrollment in a prospective observational study (NCT03164863). Treatment-naïve needle biopsies were delivered to a central laboratory where biodynamic signatures were measured in living tumor fragments challenged by standard-of-care cytotoxins. Patients received NAC per institutional guidelines and were followed through surgical intervention. A four-point classifier was trained to predict pathologic complete response (CR) then prospectively validated. Results: Among patients completing neoadjuvant treatment and surgical intervention, 33% (24 of 72) achieved CR. The biodynamic classifier predicted CR with 96% sensitivity and 97% negative predictive value. Biodynamically “favored” (scoring ≥ 3) and “strongly favored” (scoring 4) regimens produced CR at rates of 56% (23 of 41) and 73% (19 of 26), respectively. Only 3% of patients (1 of 31) achieved CR from regimens scoring 1 or 2. Area under the receiver operating curve (AUC) was 87% (95% CI: 75% to 93%, p < .0001), with similar performance across all subtypes and therapy cohorts (range: 84% to 89%). Performance of the classifier on training and validation patients was statistically equivalent. Conclusions: Biodynamic scoring accurately predicts response in breast cancer patients receiving NAC and holds promise to substantially improve management of these patients. [Table: see text]
Collapse
Affiliation(s)
| | | | | | | | | | | | - John Woods
- Indiana University Purdue University Indianapolis, Indianapolis, IN
| | | | | | | | - Ran An
- Animated Dynamics, Inc., Indianapolis, IN
| |
Collapse
|
2
|
Whitacre E, Manahan E, Burak W, Morgan T, An R, Loesch D. Abstract P3-11-17: A novel biodynamic imaging assay predicts success or failure of neoadjuvant chemotherapy in breast cancer patients. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-11-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Use of neoadjuvant chemotherapy (NAC) in breast cancer patients has increased significantly over the past decade. The clinical benefits of NAC, including potential to downstage disease, facilitation of breast conserving surgery and use of pathologic response as a prognostic marker, are well established. However, with multiple regimens approved and recommended for NAC, choosing the optimal therapy for individual patients remains a challenge. Biodynamic imaging (BI), a novel technology that captures cellular motility in living tissue via Doppler spectroscopy, could be used ex-vivo to prospectively evaluate the efficacy of systemic therapies in patient tumor samples prior to treatment. This study aimed to determine whether BI could accurately predict likelihood of response to NAC in breast cancer patients.
Methods: Fresh core biopsies were obtained from 84 patients prospectively enrolled in an IRB-approved clinical trial at 5 institutions between 1/5/17 and 8/3/2018. Patient tumor tissue was collected at time of routine diagnostic biopsy and sent to a central laboratory where it was divided into intact tumor fragments measuring approximately 1mm in diameter. Fragments were placed into 96 well plates and imaged using the BI assay (Onco4D™), while being challenged by various cytotoxic agents for up to 20 hours. Cellular characteristics and motility signatures were evaluated and compared to pathologic NAC response established upon surgical resection (mastectomy or lumpectomy).
Results: At the time of this analysis, centrally-confirmed pathologic response data were available for 17 patients treated with doxorubicin/cyclophosphamide + taxane (AC). Pathologic outcomes are pending for an additional 8 AC patients. The remainder of the 84 patients initially enrolled in the study either did not receive NAC (n=10), have not yet selected a course of therapy (n=12), or received NAC regimens other than AC (n=37). Of the 17 currently evaluable AC-treated patients, 4 had triple negative (TN) disease, 12 were hormone receptor positive, and 1 hormone receptor negative patient showed equivocal HER2 results. Two of the TN patients were known to harbor pathogenic BRCA1 mutations and received carboplatin in addition to AC. Seven of 17 patients (40%) displayed resistance to AC (2 with progressive and 5 with stable disease) while 10 experienced objective response (8 partial and 2 complete response). A multilinear regression model using 10 BI markers accurately classified 16 of 17 patients (94%) while producing 1 false prediction of partial response for a patient with stable disease clinically (R-squared=0.9994, p<.0001). The positive predictive and negative predictive values of BI to AC response were 100% and 91%, respectively.
Table 1.Performance Characteristics Clinical OutcomeResponseNon-ResponseTotalClassifierResponse10111 Non-Response066 Total10717
Conclusion: BI was able to accurately predict patient response to neoadjuvant AC, demonstrating the potential for the platform to support personalized patient therapy. This clinical trial is ongoing and will report out results for TC (docetaxel/cyclophosphamide), TCHP (docetaxel/carboplatin/trastuzumab + pertuzumab), and additional AC patients as outcome data are accrued.
Citation Format: Whitacre E, Manahan E, Burak W, Morgan T, An R, Loesch D. A novel biodynamic imaging assay predicts success or failure of neoadjuvant chemotherapy in breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-11-17.
Collapse
Affiliation(s)
- E Whitacre
- Breast Center of Southern Arizona, Tucson, AZ; Dalton Surgical Group, Dalton, GA; Memorial Health University Medical Center, Savannah, GA; Animated Dynamics, Inc., Indianapolis, IN
| | - E Manahan
- Breast Center of Southern Arizona, Tucson, AZ; Dalton Surgical Group, Dalton, GA; Memorial Health University Medical Center, Savannah, GA; Animated Dynamics, Inc., Indianapolis, IN
| | - W Burak
- Breast Center of Southern Arizona, Tucson, AZ; Dalton Surgical Group, Dalton, GA; Memorial Health University Medical Center, Savannah, GA; Animated Dynamics, Inc., Indianapolis, IN
| | - T Morgan
- Breast Center of Southern Arizona, Tucson, AZ; Dalton Surgical Group, Dalton, GA; Memorial Health University Medical Center, Savannah, GA; Animated Dynamics, Inc., Indianapolis, IN
| | - R An
- Breast Center of Southern Arizona, Tucson, AZ; Dalton Surgical Group, Dalton, GA; Memorial Health University Medical Center, Savannah, GA; Animated Dynamics, Inc., Indianapolis, IN
| | - D Loesch
- Breast Center of Southern Arizona, Tucson, AZ; Dalton Surgical Group, Dalton, GA; Memorial Health University Medical Center, Savannah, GA; Animated Dynamics, Inc., Indianapolis, IN
| |
Collapse
|
3
|
Whitworth PW, Graham C, Schonholz S, Manahan E, Phillips R, Robertson Y, Hardwick MK. Abstract P3-13-10: Minimally-invasive (percutaneous) stereotactic and ultrasound-guided lumpectomy for DCIS and small breast cancers. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-13-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
In spite of advances characterizing the biology of individual breast cancers, current analytics cannot adequately identify truly indolent lesions. As a result many indolent breast cancers and DCIS are over-treated in order to avoid under-treatment of truly life-threatening cancers. Reducing over-treatment for DCIS and small cancers is a current priority for breast cancer management, to optimize both patient care and resource utilization. Intact minimally-invasive excision (percutaneous lumpectomy) with radiofrequency basket capture can eliminate the need for open excision of many atypical ductal hyperplasia (ADH) breast lesions (Whitworth, et al, Ann Surg Oncol, 2011). Percutaneous lumpectomy provides standard margin and lesion analysis of the specimen, accomplishing the same goals as open excision. Here we report results of the IPEX study, a prospective phase 4 trial evaluating the same minimally-invasive strategy when employed to manage small breast cancers and DCIS.
Methods
94 women age 31-86 had minimally-invasive (percutaneous) removal of DCIS or small breast cancers using a 20 mm radiofrequency basket capture technique with stereotactic or ultrasound guidance. Tissue elasticity permitted removal through a small incision (less than 10 mm). A second 20 mm basket capture was used to shave and further evaluate margins. Procedures were conducted with adequate local anesthesia and P.O. sedation in the imaging department. Patient tolerance scores were recorded. Standard radiologic evaluation (specimen and breast) and histologic criteria were applied in all cases. Standard open sentinel node biopsy was offered to patients with invasive breast cancers. All patients provided informed consent for the study.
Results
Final histologic lesion size was 1-20 mm. Of 40 DCIS and 54 invasive lesions, 18 (19%) had positive margins and/or open re-excision, including one patient who had re-excision in spite of negative margins because of inadequate shaved-margin quality (no residual disease on pathology). 58 patients completed APBI (balloon or strut-based brachytherapy) and 16 had whole breast radiation. Of 54 patients with invasive cancers, 34 (age 66-86) had no sentinel node biopsy based on patient preference and low risk features. Patient pain scores averaged 1.9 out of 10 (range 0-7).
Conclusions
Minimally-invasive (percutaneous) lumpectomy provides satisfactory management of DCIS and small breast cancers, accomplishing the same goals as open surgery. The specimen is intact so the pathologist can conduct standard histologic analysis of the lesion, distinguishing DCIS, ADH and invasive cancer. Margin analysis is standard. Compared to open surgery, less tissue can be removed because of small lesion size with more precise targeting and resection. Minimally-invasive (percutaneous) lumpectomy reduces morbidity, distress, discomfort and expense associated with overtreatment of small breast cancers.
Citation Format: Whitworth PW, Graham C, Schonholz S, Manahan E, Phillips R, Robertson Y, Hardwick MK. Minimally-invasive (percutaneous) stereotactic and ultrasound-guided lumpectomy for DCIS and small breast cancers. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-13-10.
Collapse
Affiliation(s)
- PW Whitworth
- Nashville Breast Center, Nashville, TN; Southwest General, Middleburg Heights, OH; Baystate Noble Hospital, Westfield, MA; Dalton Surgical Group, Dalton, GA; Metro Surgical Associates, Atlanta, GA; TME Research, Allentown, PA
| | - C Graham
- Nashville Breast Center, Nashville, TN; Southwest General, Middleburg Heights, OH; Baystate Noble Hospital, Westfield, MA; Dalton Surgical Group, Dalton, GA; Metro Surgical Associates, Atlanta, GA; TME Research, Allentown, PA
| | - S Schonholz
- Nashville Breast Center, Nashville, TN; Southwest General, Middleburg Heights, OH; Baystate Noble Hospital, Westfield, MA; Dalton Surgical Group, Dalton, GA; Metro Surgical Associates, Atlanta, GA; TME Research, Allentown, PA
| | - E Manahan
- Nashville Breast Center, Nashville, TN; Southwest General, Middleburg Heights, OH; Baystate Noble Hospital, Westfield, MA; Dalton Surgical Group, Dalton, GA; Metro Surgical Associates, Atlanta, GA; TME Research, Allentown, PA
| | - R Phillips
- Nashville Breast Center, Nashville, TN; Southwest General, Middleburg Heights, OH; Baystate Noble Hospital, Westfield, MA; Dalton Surgical Group, Dalton, GA; Metro Surgical Associates, Atlanta, GA; TME Research, Allentown, PA
| | - Y Robertson
- Nashville Breast Center, Nashville, TN; Southwest General, Middleburg Heights, OH; Baystate Noble Hospital, Westfield, MA; Dalton Surgical Group, Dalton, GA; Metro Surgical Associates, Atlanta, GA; TME Research, Allentown, PA
| | - MK Hardwick
- Nashville Breast Center, Nashville, TN; Southwest General, Middleburg Heights, OH; Baystate Noble Hospital, Westfield, MA; Dalton Surgical Group, Dalton, GA; Metro Surgical Associates, Atlanta, GA; TME Research, Allentown, PA
| |
Collapse
|
4
|
Holmes D, Colfry A, Czerniecki B, Dickson-Witmer D, Francisco Espinel C, Feldman E, Gallagher K, Greenup R, Herrmann V, Kuerer H, Malik M, Manahan E, O'Neill J, Patel M, Sebastian M, Wheeler A, Kass R. Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer. Ann Surg Oncol 2015. [PMID: 26224406 DOI: 10.1245/s10434-015-4753-3] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
PURPOSE The American Society of Breast Surgeons (ASBrS) sought to provide an evidence-based guideline on the use of neoadjuvant systemic therapy (NST) in the management of clinical stage II and III invasive breast cancer. METHODS A comprehensive nonsystematic review was performed of selected peer-reviewed literature published since 2000. The Education Committee of the ASBrS convened to develop guideline recommendations. RESULTS A performance and practice guideline was prepared to outline the baseline assessment and perioperative management of patients with clinical stage II-III breast cancer under consideration for NST. RECOMMENDATIONS Preoperative or NST is emerging as an important initial strategy for the management of invasive breast cancer. From the surgeon's perspective, the primary goal of NST is to increase the resectability of locally advanced breast cancer, increase the feasibility of breast-conserving surgery and sentinel node biopsy, and decrease surgical morbidity. To ensure optimal patient selection and efficient patient care, the guideline recommends: (1) baseline breast and axillary imaging; (2) minimally invasive biopsies of breast and axillary lesions; (3) determination of tumor biomarkers; (4) systemic staging; (5) care coordination, including referrals to medical oncology, radiation oncology, plastic surgery, social work, and genetic counseling, if indicated; (6) initiation of NST; (7) post-NST breast and axillary imaging; and (8) decision for surgery based on extent of disease at presentation, patient choice, clinical response to NST, and genetic testing results, if performed.
Collapse
Affiliation(s)
- Dennis Holmes
- Department of Surgery, Los Angeles Center for Women's Health, Los Angeles, CA, USA,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Manahan E, Wang L, Chen S, Dickson-Witmer D, Zhu J, Holmes D, Kass R. What is a Breast Surgeon Worth? A Salary Survey of the American Society of Breast Surgeons. Ann Surg Oncol 2015. [DOI: 10.1245/s10434-015-4720-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
6
|
McKeown C, Toomey D, Manahan E, Murphy J, Conlon K. Vascular Endothelial Growth Factor production in breast cancer is reduced by Camptothecin regardless of Cyclooxygenase-2 expression. Eur J Surg Oncol 2008. [DOI: 10.1016/j.ejso.2008.06.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
7
|
Ponce J, Haynes B, Paynter S, Fromm R, Lindsey B, Shafer A, Manahan E, Sutterfield C. Effect of Lap-Band-induced weight loss on type 2 diabetes mellitus and hypertension. Obes Surg 2005; 14:1335-42. [PMID: 15603648 DOI: 10.1381/0960892042583932] [Citation(s) in RCA: 91] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Severe obesity is associated with type 2 diabetes and hypertension. Improvement in these comorbidities after surgically-induced weight loss has been documented, and laparoscopic adjustable gastric banding (LAGB) is an effective weight loss operation. METHODS Of 840 patients who underwent Lap-Band, data are available in 402 out of 413 patients whose surgery took place at >/= 1 year ago. Preoperative and follow-up data were studied retrospectively to examine the effect of Lap-Band-induced weight loss on diabetes and hypertension. RESULTS Of 413 patients with at least 1 year postoperative follow-up, 53 (12.8%) were taking medications for type 2 diabetes preoperatively and 189 (45.7%) were on antihypertensive medications. 66% (n=35) of diabetic patients were also hypertensive. Resolution of diabetes was observed in 66% at 1-year and 80% at 2-year follow-up. HbA1c dropped from 7.25% (5.6-11.0, n=53) preoperatively to 5.58% (5.0-6.2, n=15) at 2 years after surgery. Hypertension resolved in 59.8% and 74% at 1 and 2 years, respectively. Percent excess weight loss (%EWL) was lower for diabetic patients than for our cohort population (39.2% vs 41.2% at 1 year, 46.7% vs 54.2% at 18 months, and 52.6% vs 63.3% at 2 years, respectively). Patients in whom diabetes was improved but not resolved had lower %EWL than did those whose diabetes went into remission (27.0% at 1 year and 26.5% at 2 years). Patients with the shortest duration of diabetes (<5 years) and better weight loss after surgery achieved higher resolution rates. CONCLUSIONS Dramatic improvement in - and frequent resolution of - diabetes and hypertension have been observed as a result of weight loss after Lap-Band surgery.
Collapse
Affiliation(s)
- Jaime Ponce
- Dalton Surgical Group, P. C. and Hamilton Medical Center, Dalton, GA 30720, USA.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Lopez S, Manahan E, Evans JR, Kao RL, Browder W. Third place winner of the Conrad Jobst Award in the gold medal paper competition. Prevention of spinal cord dysfunction in a new model of spinal cord ischemia. Am Surg 1995; 61:16-20. [PMID: 7832375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Paraplegia or paraparesis caused by temporary cross-clamping of the aorta is a devastating sequela in patients after surgery of the thoracoabdominal aorta. No effective clinical method is available to protect the spinal cord from ischemic reperfusion injury. A small animal (rat) model of spinal cord ischemia is established to better understand the pathophysiological events and to evaluate potential treatments. Eighty-one male Sprague-Dawley rats weighing 300 g to 350 g were used for model development (45) and treatment evaluation (36). The heparinized and anesthetized rat was supported by a respirator following tracheostomy. The thoracic aorta was cannulated via the left carotid artery for post-clamping intra-aortic treatment solution administration. After thoracotomy, the aorta was freed and temporarily clamped just distal to the left subclavian artery and just proximal to the diaphragm for different time intervals: 0, 5, 10, 15, 20, 25, 30, 35, and 40 minutes (five animals per group). The motor function of the lower extremities postoperatively showed consistent impairment after 30 minutes clamping (5/5 rats were paralyzed), and this time interval was used for treatment evaluation. For each treatment, six animals per group were used, and direct local intra-aortic infusion of physiologic solution (2 mL) at different temperatures with or without buffer substances was given immediately after double cross-clamp to protect the ischemic spinal cord. Arterial blood (2 mL) was infused in the control group. The data indicate that the addition of HCO3-(20 mM) to the hypothermic (15 degrees C) solution offered complete protection of the spinal cord from ischemic injury.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- S Lopez
- Department of Surgery, East Tennessee State University, Johnson City 37614-0575
| | | | | | | | | |
Collapse
|